Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board of Directors Meeting

Date of Board Meeting / Approval: August 14, 2026

Audit Opinion: Clean (No modifications or qualifications)

Auditor's Comment: Statutory auditors conducted limited review and reported nothing came to their attention causing belief that the statement contains material misstatement.

Key Financial Highlights [Rs. in Lakhs]

Standalone Results:

Revenue from Operations: ₹2,608.18 lakhs (Q1 FY27) vs ₹2,269.12 lakhs (Q1 FY26) - 14.9% YoY increase

Total Income: ₹2,612.76 lakhs (Q1 FY27) vs ₹2,278.06 lakhs (Q1 FY26)

Net Profit: ₹224.61 lakhs (Q1 FY27) vs ₹120.73 lakhs (Q1 FY26) - 86% YoY increase

EPS: ₹2.24 (Q1 FY27) vs ₹1.20 (Q1 FY26)

Other Equity Reserves: ₹6,541.54 lakhs (as of March 31, 2026)

Consolidated Results:

Revenue from Operations: ₹2,608.18 lakhs (Q1 FY27) vs ₹2,237.23 lakhs (Q1 FY26) - 16.6% YoY increase

Total Income: ₹2,612.76 lakhs (Q1 FY27) vs ₹2,246.48 lakhs (Q1 FY26)

Net Profit: ₹223.13 lakhs (Q1 FY27) vs ₹130.70 lakhs (Q1 FY26) - 70.7% YoY increase

EPS: ₹2.22 (Q1 FY27) vs ₹1.30 (Q1 FY26)

Other Equity Reserves: ₹6,549.20 lakhs (as of March 31, 2026)

Expense Breakdown (Standalone Q1 FY27):

  • Cost of materials consumed: ₹1,061.42 lakhs
  • Purchase of stock-in-trade: ₹140.31 lakhs
  • Employee benefits expense: ₹418.05 lakhs
  • Finance cost: ₹93.18 lakhs
  • Depreciation and amortization: ₹77.06 lakhs
  • Other expenses: ₹572.84 lakhs

Tax Expenses (Standalone Q1 FY27):

  • Current tax: ₹60.80 lakhs
  • Deferred tax: ₹16.22 lakhs
  • Total tax: ₹77.02 lakhs

Segment-wise Performance:

The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.

Corporate Actions:

The Board approved the incorporation of a subsidiary in the Philippines with the following details:

  • Name: Gufic Philippines Inc. (or other approved name)
  • Investment: Up to USD 250,000 by cash subscription
  • Shareholding: Company to hold approximately 99.99% equity
  • Timeline: To be incorporated within 12 months
  • Business Purpose: Marketing, sale, distribution and other allied activities of pharmaceutical products in the Philippines, including holding and managing Intellectual Property Rights
  • Regulatory Approvals Required: Incorporation/registration with Philippines SEC, pharmaceutical regulatory approvals/licenses, and compliance with Indian foreign exchange regulations

Other Significant Information:

  • Paid-up equity share capital: ₹100.28 lakhs
  • Face value of equity share: ₹1.00
  • The meeting commenced at 5:00 p.m. and concluded at 6:10 p.m.